摘要
目的系统评价阿瑞匹坦与福沙匹坦预防高致吐性化疗(HEC)相关恶心、呕吐的疗效及安全性。方法计算机检索Embase、PubMed、Cochrane Library、知网、万方、维普自建库至2022年12月有关福沙匹坦和阿瑞匹坦预防HEC相关恶心呕吐疗效与安全性的随机对照试验。2名研究者独立筛选并评价偏倚风险后,采用RevMan 5.4软件进行meta分析。结果最终纳入7篇文献,共4932例患者。meta分析结果显示,福沙匹坦与阿瑞匹坦总观察期及延迟期呕吐完全缓解率,总观察期、急性期、延迟期呕吐完全控制率,解救治疗比例,不良反应发生率方面差异均无统计学意义(P>0.05);福沙匹坦急性期呕吐完全缓解率高于阿瑞匹坦[RR=1.02,95%CI(1.00,1.04),P<0.05]。结论福沙匹坦和阿瑞匹坦预防HEC相关恶心呕吐效果相当,患者耐受性较好,福沙匹坦预防急性期呕吐优于阿瑞匹坦。
Objective To systematically evaluate the efficacy and safety of aprepitant and fosaprepitant in the prevention of highly emetogenic chemotherapy(HEC)related nausea and vomiting.Methods Randomized controlled trials were searched by computer from Embase,PubMed,Cochrane Library,CNKI,Wanfang,and VIP databases on the efficacy and safety of fosaprepitant and aprepitant in the prevention of HEC related nausea and vomiting,with the retrieval time limit from the establishment of the database until December 2022.After independently screening and evaluating the risk of bias,two investigators used RevMan 5.4 software for Meta-analysis.Results Finally,7 articles were included,involving 4932 patients.The Meta-analysis results showed that there was no significant difference in total complete remission rate of vomiting in the observation period and delay period,total complete control rate of vomiting in the observation period,acute period,and delay period,salvage treatment proportion,and incidence of adverse reactions between fosaprepitant and aprepitant(P>0.05).The complete remission rate of vomiting in the acute period of fosaprepitant was higher than that of aprepitant(RR=1.02,95%CI[1.00,1.04],P<0.05).Conclusion Fosaprepitant and aprepitant have equivalent preventive effects on nausea and vomiting associated with HEC,and patients have good tolerance.Fosaprepitant is superior to aprepitant in preventing vomiting in the acute period.
作者
齐晓艳
寇祥伟
陈苏婉
刘丽丽
孙敏
QI Xiaoyan;KOU Xiangwei;CHEN Suwan;LIU Lili;SUN Min(Department of Pharmacy,the People’s Hospital of Rizhao,Shandong,Rizhao 276826,China;Department of Oncology,the People’s Hospital of Rizhao,Shandong,Rizhao 276826,China)
出处
《中国医药科学》
2024年第2期87-90,共4页
China Medicine And Pharmacy
基金
北京康盟慈善基金会医学科研发展基金项目-临床与基础研究专项(TB205003)
山东省卫生健康委员会第二批药品临床综合评价项目(2022YZ020)。
关键词
化疗药物相关恶心呕吐
高致吐性化疗
阿瑞匹坦
福沙匹坦
META分析
Nausea and vomiting associated with chemotherapy drugs
Highly emetogenic chemotherapy
Aprepitant
Fosaprepitant
Meta-analysis
